8-KOther EventsExhibits & Filings

BRISTOL MYERS SQUIBB CO 8-K Report, Corporate Update (Feb 27, 2017)

Filed February 27, 2017For Securities:BMYCELG-RIBMYMP

Summary

Bristol-Myers Squibb Company (BMY) filed an 8-K on February 27, 2017, to report on the closing of a significant debt offering. The company successfully sold $1.5 billion in aggregate principal amount of notes, comprising $750 million of 1.600% notes due in 2019 and $750 million of 3.250% notes due in 2027. This debt issuance provides the company with additional capital, which could be utilized for various corporate purposes such as funding operations, research and development, potential acquisitions, or general corporate needs. The specific terms and interest rates indicate a strategic move to manage the company's debt structure and potentially lower its overall cost of borrowing or extend its debt maturity profile.

Key Highlights

  • 1BMY closed a debt offering on February 27, 2017, raising substantial capital.
  • 2The offering consisted of $750 million in 1.600% notes due 2019.
  • 3The offering also included $750 million in 3.250% notes due 2027.
  • 4The total aggregate principal amount of notes sold was $1.5 billion.
  • 5The notes were issued under an existing Indenture, as supplemented by a Ninth Supplemental Indenture.
  • 6The offering was conducted through an Underwriting Agreement with Goldman, Sachs & Co., Morgan Stanley & Co. LLC, and Merrill Lynch, Pierce, Fenner & Smith Incorporated as representatives.
  • 7The sale of these notes was registered under the Securities Act of 1933.

Frequently Asked Questions

This 8-K filing reports on the closing of Bristol-Myers Squibb's debt offering, where they sold $1.5 billion in notes to raise capital.

BMY raised a total of $1.5 billion by issuing two series of notes: $750 million of 1.600% notes due 2019 and $750 million of 3.250% notes due 2027.

The company issued $750 million of notes with a 1.600% coupon due in 2019, and $750 million of notes with a 3.250% coupon due in 2027.

While not explicitly stated in this filing, proceeds from debt offerings are typically used for general corporate purposes, which can include funding operations, research and development, capital expenditures, acquisitions, or refinancing existing debt.